Arcus Biosciences

Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. It competes in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Arcus Biosciences reports strong Q3 performance with promising trial results

Arcus Biosciences delivered strong financial performance and promising clinical trial results in Q3 2023.
The company faces financial challenges amidst high R&D expenses but maintains a solid cash position and operational strength.
Strategic opportunities exist in advancing differentiated therapies, navigating competitive landscapes, and exploring combination treatments.
Successfully addressing challenges and capitalizing on opportunities can drive growth and market success for Arcus Biosciences.

Arcus Biosciences excels in Q4, poised for oncology innovation

Arcus Biosciences reported strong financials, positive program results, and strategic partnerships, positioning the company for continued growth and innovation in oncology.
Operational changes reflect a proactive approach to portfolio optimization and trial advancement, demonstrating Arcus's commitment to maximizing program potential and patient impact.
Challenges in data interpretation, program comparisons, and trial planning require careful navigation, while upcoming opportunities in 2024 offer avenues for showcasing progress and driving future success.
With a focus on expanding patient cohorts, optimizing doses, and revealing trial designs, Arcus is poised to capitalize on opportunities, address challenges, and deliver value to stakeholders.

Arcus Biosciences reports robust Q1 results and advances promising pipeline

Arcus Biosciences showcased strong financials, positive study data, and strategic partnerships, positioning them well for future growth and innovation.
While facing challenges in managing expenses and differentiation strategies, the company is actively exploring opportunities in combination therapies and tumor targeting.
The emphasis on good data, strategic planning, and leveraging biological insights highlights Arcus Biosciences' commitment to advancing drug development efforts and improving patient outcomes.

Arcus Biosciences reports promising clinical results and solid financials

Arcus Biosciences demonstrated strong clinical progress with casdatifan and domvanalimab, supported by solid financial performance. While challenges in clinical trial execution and market competition exist, the company is well-positioned to capitalize on opportunities for growth through upcoming Phase 3 studies and data presentations.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the company will report its financial results for the second quarter ended June 30, 2021 after the market closes on Thursday, August 5, 2021. Management will host a conference call on August 5, 2021 to discuss second quarter 2021 financial results and recent corporate highlights. The call will begin at 1:30 pm

Arcus Biosciences to Report Second Quarter 2021 Financial Results & Recent Corporate Highlights

The stock price of Arcus Biosciences Inc (NYSE: RCUS) increased by 8.03% today. This is why it happened.

RCUS Stock Increased 8.03%: Why It Happened

Arcus Biosciences, Inc. (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Arcus Biosciences, Inc. (RCUS) Stock Jumps 15.5%: Will It Continue to Soar?

No news from Arcus Biosciences is bad news for the company and other industry heavyweights.

Why Arcus Biosciences' Big Reveal Wasn't Very Exciting

Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.

Here's Why Arcus Biosciences Stock Is Rising Today

Shares of Arcus Biosciences Inc. gained 19.8% in trading on Thursday, the day after the company said its experimental lung-cancer PD-L1 treatment demonstrated clinical activity in an open-label, Phase 2 clinical study. Arcus did not release specific data but said the trial will continue.

Arcus stock jumps 19% after announcing it will move forward with trial for lung-cancer treatment

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, at the first interim analysis of the three-arm randomized Phase 2 ARC-7 study, both arms with domvanalimab-based combinations showed encouraging clinical activity (measured by overall response rate; ORR) when given as an initial treatment (first-line) to people with metastatic, PD-L1≥50% non-small cell lung c

Anti-TIGIT Domvanalimab-Based Combinations Showed Encouraging Clinical Activity in People with Metastatic, PDL1-High Non-Small Cell Lung Cancer at First Interim Analysis of Arcus Biosciences' Randomized Phase 2 ARC-7 Study

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced initial efficacy and safety data from one of the cohorts in ARC-6, a randomized Phase 1b/2 platform study, evaluating the novel combination of etrumadenant (dual adenosine A2a/A2b receptor antagonist) plus zimberelimab (anti-PD1 antibody) and docetaxel in people with taxane-naïve mCRPC who progressed following trea

Arcus Biosciences Presents Early Data from ARC-6, a Phase 1b/2 Study Evaluating Etrumadenant-Based Combinations in Metastatic Castrate-Resistant Prostate Cancer at the 2021 ASCO Annual Meeting

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the first quarter ended March 31, 2021 and provided operational highlights. “Our ongoing clinical trials include six randomized studies with several that are expected to provide meaningful readouts over the next 12 months,” said Terry Rosen, Ph.D., CEO. “We expect the next milestone in our anti

Arcus Biosciences Reports First Quarter 2021 Financial Results and Provides Operational Highlights

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free survival (PFS) and overall survival (OS) data in patients with advanced metastatic colorectal cancer (mCRC) from the ARC-3 study at the 2021 American Association for Cancer Research (AACR) Annual Meeting. ARC-3 was a Phase 1/1b, multicenter, open-label, dose-escalation and dose-expansion study that

Arcus Biosciences Presents Updated Data for Etrumadenant in Third-Line Metastatic Colorectal Cancer and New Data on its HIF-2α Program at the AACR 2021 Annual Meeting

Arcus Biosciences, Inc. (RCUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Arcus Biosciences, Inc. (RCUS) Stock Jumps 9.5%: Will It Continue to Soar?

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results for the fourth quarter and year ended December 31, 2020 and provided operational highlights. “With $735 million in cash at the end of the year, plus $220 million from Gilead's recent equity investment, we are extremely well-positioned to accelerate the advancement of our pipeline, initiate our firs

Arcus Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Operational Highlights

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the following upcoming 2021 virtual investor conferences: 10th Annual SVB Leerink Global Healthcare Conference, Friday, February 26 at 12:00 pm ET Cowen 41st Annual Health Care Conference, Tuesday, March 2 at 11:10 am ET Barclays Global Healthcare Conference, Wednesday, March 10 at 1

Arcus Biosciences to Participate in Upcoming Investor Conferences

Gilead Sciences

Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Arcus shares were still inactive in premarket trading.

Gilead buys more Arcus Biosciences stock, at a price above the record close

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Gilead Sciences is increasing its ownership in Arcus to 19.5%, from approximately 13%, by purchasing 5,650,000 additional shares of Arcus's common stock at a per share purchase price of $39.00. “Gilead's additional investment in Arcus demonstrates the strength of our relationship, a recognition of the depth of

Gilead Sciences to Increase Its Ownership In Arcus Biosciences

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data from the dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in metastatic pancreatic cancer at the ASCO 2021 Virtual Gastrointestinal Cancers Symposium (ASCO GI). The ongoing, open-labe

Arcus Biosciences Presents Promising Initial Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary data from the ongoing dose-escalation portion of its ARC-8 Phase 1/1b study, evaluating the safety and tolerability of AB680, the first small-molecule CD73 inhibitor to enter the clinic, in combination with zimberelimab (anti-PD-1) and nab-paclitaxel plus gemcitabine (chemotherapy) in front-line me

Arcus Biosciences to Present Preliminary Data from Phase 1 Portion of ARC-8 Study for AB680 in Metastatic Pancreatic Cancer at ASCO-GI Symposium

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman, M.D., Ph.D. and Michael Quigley, Ph.D. have joined the Company's Board of Directors. Dr. Perlman will also serve as a member of Arcus's Nominating and Corporate Governance Committee. Drs. Perlman and Quigley both have outstanding track records of success working in innovative and intensely comp

Arcus Biosciences Appoints Biotech Industry Veteran, Andrew Perlman, M.D., Ph.D. and Gilead's SVP of Research Biology, Michael Quigley, Ph.D.

Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Arcus Biosciences (RCUS) Stock?

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a global company with leading open-access biologics technology platforms, today announced an expansion of their existing strategic relationship under which the parties will discover anti-CD39 antibodies using WuXi Bio's proprietary technology. This CD39 collaboration represents the fourth antibody dev

Arcus Biosciences Expands Strategic Relationship with WuXi Biologics to Develop a Best-in-Class anti-CD39 Antibody for the Treatment of Cancer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management will present at the Evercore ISI 3rd Annual HealthCONx Virtual Conference on Wednesday, December 2, 2020 at 10:30 a.m. Eastern Time. A live audio webcast of the presentation will be available by visiting the “Investors” section of the Arcus website at www.arcusbio.com. A replay of the webcast will b

Arcus Biosciences to Participate in the Evercore ISI 3rd Annual HealthCONx Virtual Conference

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results for the third quarter ended September 30, 2020 and provided corporate updates. “Our progress in 2020 has significantly de-risked the viability of Arcus's ambitions to become a long-term independent biopharmaceutical company,” said Terry Rosen, Ph.D., CEO. “With the continued advancement of our fou

Arcus Biosciences Announces Third Quarter 2020 Financial Results and Corporate Updates

AstraZeneca

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to evaluate domvanalimab (AB154), Arcus's investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer (NSCLC). Imfinzi is the only im

Arcus to Collaborate With AstraZeneca on Registrational Trial for Domvanalimab, Arcus's Novel Anti-TIGIT Antibody, Plus Imfinzi® in Stage III NSCLC

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarrett has rejoined Arcus as Chief Operating Officer with responsibility for Arcus’s commercial and general & administrative organizations, including finance and human resources. Ms. Jarrett is an accomplished executive in the healthcare and technology industries. She has a consistent track recor

Jennifer Jarrett Returns to Arcus Biosciences as Chief Operating Officer

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

News for Arcus Biosciences Stock (RCUS)